Over 100 Delegates attend Oxford Gene Technology Ltd.'s aCGH Workshop at American Society of Human Genetics 2010
Published: Nov 11, 2010
Professor Stephen Rich, Director of the University of Virginia Center for Public Health Genomics, presented details of how his group are using OGT’s Genefficiency™ aCGH technology as the basis of a pioneering study exploring the relationships between genome copy number variation and type 1 diabetes. Following this was a talk by Professor David Ledbetter, Chief Scientific Officer of Geisinger Health System, who provided updates on recent developments regarding the International Standards for Cytogenomic Arrays (ISCA) Consortium and the ISCA Database, as well as discussing recent data describing the detection of uniparental disomy (UPD) using OGT’s new CytoSure™ ISCA UPD array.
Dr Mike Evans, OGT’s CEO, who also presented at the meeting, commented: “It was a very well-received series of presentations, and very gratifying to see such interest in OGT’s work at the forefront of microarray development.” Dr Evans continued, “Our ongoing collaborations with internationally esteemed researchers and consortia, such as Professor Rich, Professor Ledbetter and ISCA, are testament to OGT’s dedication to providing outstanding microarray products and services.”
To see the presentations from the OGT Workshop, visit www.ogt.co.uk/go/ashg2010.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Sandy Lane, Yarnton, Oxford OX5 1PF T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: firstname.lastname@example.org W: www.ogt.co.uk
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.
Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high quality genomic data to customers worldwide. The OGT CytoSure™ cytogenetics array, labelling and interpretation software products and services provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.
Biomarker Discovery: OGT has a proven pedigree in genomic technology, which, together with the experience gained through the purchase of Sense Proteomics in 2009, enables OGT to develop highly specific customised genomic and proteomic biomarker panels for cancer and other diseases. OGT develops these for clinical screening and companion diagnostics requirements, both for direct sale and also for collaboration with partner companies.
CytoSure™: For research use only This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT FOR DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.